Actelion, with headquarters near Basel, Switzerland is an independent biopharmaceutical company focused on the discovery and development for the market of novel therapeutics for serious and unmet medical conditions.
Participated at Bio/PharMOS-Bio/PharDOS 2006
Objectives : Through the company's comprehensive life cycle and label expansion management strategy Actelion aims to develop products to their maximum potential. With line extensions and new indications, for example, since the company gained approval to market TracleerŪ in 2001, the company has continued to invest in further clinical trials so as to expand its use into new indications.
About us : Actelion enjoys a proven track record in drug discovery, aiming to discover, or to in-license and develop, a steady stream of new products as sources of revenue.
The novel entitites are derived from 'first-in class' small moleculare weight compounds. Actelion's priority focus on innovative treatments for unmet medical needs, determines Actelion's approach towards new drugs that can bring therapeutic advantage both to patients as well as an economic benefit for the community at large.
